Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study

Table 2 Regression analysis for MV duration and LOS

Outcomes	Crude analysis		p-value	Beta coefficient (estimates) (95% CI)	p-value^$*
Outcomes	Control group	Tocilizumab group	p-value	Beta coefficient (estimates) (95% CI)	p-value^$*
MV duration during ICU stay days, median (Q1, Q3)^&#	9.0 (4.0, 17.0)	10.0 (4.0, 18.0)	0.46	0.06 (− 0.11, 0.22)	0.49
ICU length of stay days, median (Q1, Q3)^&	8.0 (5.0, 13.0)	9.0 (6.0, 15.0)	0.01	0.12 (− 0.05, 0.29)	0.16
Hospital length of stay days, median (Q1, Q3)^&	16.0 (11.0, 26.0)	18.0 (13.0, 27.5)	0.04	0.15 (− 0.00, 0.29)	0.05

^$*Multivariable negative binomial regression is used after adjusting for patient’s age, SOFA score, PaO₂/FiO₂ ratio baseline and systemic corticosteroids during ICU stay to calculate estimates and p-value
^&^#Denominator is patients who have respiratory failure requiring MV during ICU stay
^&Denominator is patients who survived

ISSN: 1471-2334